Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette–Guérin?
BJU International  (IF5.588),  Pub Date : 2021-12-01, DOI: 10.1111/bju.15665
Niyati Lobo, Patrick J. Hensley, Kelly K. Bree, Graciela M. Nogueras-Gonzalez, Neema Navai, Colin P. Dinney, Ashish M. Kamat

To determine the impact of fibrin clot inhibitor (FCI) use on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate bacille Calmette–Guérin (BCG).